Manoj Menon is an Oncology physician affiliated with University of Washington. OpenAlex indexes 85 publications with 1,502 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
325 9th Ave
Seattle, WA 981042420
Telephone
206-744-3241Registry record last updated 28 Jul 2014.
Clinical trials
- Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Sponsor: Fred Hutchinson Cancer Center
- Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
Sponsor: Fred Hutchinson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.5%Cytochrome P450 17A1 Inhibitor22.6%Abiraterone Acetate100%Part D<11 patientsKinase inhibitor16.8%Bosulif52%Calquence48%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
23.4%Corticosteroid23.4%Prednisone100%Part D<11 patientsDermatology
10.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.9%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Core K: Biomarkers, Prevention and Interventions for HIV-associated Malignancies and NCDs
University of Washington
FY2026$233,140P30AI027757 - Core K: Biomarkers, Prevention and Interventions for HIV-associated Malignancies and NCDs
University of Washington
FY2025$277,730P30AI027757 - Core K: Biomarkers, Prevention and Interventions for HIV-associated Malignancies and NCDs
University of Washington
FY2024$189,865P30AI027757
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Journal for ImmunoTherapy of Cancer
2025 - A Systematic Review of Prolonged SARS‐CoV‐2 Shedding in Immunocompromised Persons
Influenza and Other Respiratory Viruses
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”